-

Circle Pharma Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced management will participate in upcoming investor conferences in November:

  • LifeSci Growth & Innovation Summit
    November 17, 2025
    Participants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officer
    Location: London, UK
  • Jefferies Global Healthcare Conference - London
    November 18-20, 2025
    Participants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officer
    Location: London, UK

About Circle Pharma

Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

Industry:

Circle Pharma, Inc.

Release Versions
English

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

More News From Circle Pharma, Inc.

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the nomination of CID-165, a first-in-class, orally bioavailable macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program. Cyclin D1 is a regulatory protein that plays a crucial role in cell cycle progression and is overexpressed or translocated in malignancie...

Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the appointment of Anne E. Borgman, M.D., as chief medical officer. Dr. Borgman is an accomplished chief medical officer, business executive, scientific advisor and board director with more than 20 years of experience devising and executing clinical development strategies that have led to multiple on...

Circle Pharma Appoints Rob Lauzen as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the appointment of Rob Lauzen as chief financial officer. Mr. Lauzen brings deep financial expertise and broad experience within the life sciences industry, having most recently served as chief financial officer of Prilenia Therapeutics, where he oversaw all aspects of the company’s capital strategy,...
Back to Newsroom